JP2014530861A - Ｔｏｒキナーゼ阻害剤を用いたがんの処置 - Google Patents

Ｔｏｒキナーゼ阻害剤を用いたがんの処置 Download PDF

Info

Publication number
JP2014530861A
JP2014530861A JP2014537216A JP2014537216A JP2014530861A JP 2014530861 A JP2014530861 A JP 2014530861A JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014537216 A JP2014537216 A JP 2014537216A JP 2014530861 A JP2014530861 A JP 2014530861A
Authority
JP
Japan
Prior art keywords
formula
substituted
unsubstituted
pyrazin
tor kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014537216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530861A5 (cg-RX-API-DMAC7.html
Inventor
シュ，シュイチャン
ヘゲ，クリステン，メイ
ロペス−ジローナ，アントニア
レイモン，ヘザー
ナーラ，ラマ，ケー．
チョプラ，ラジェッシュ
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2014530861A publication Critical patent/JP2014530861A/ja
Publication of JP2014530861A5 publication Critical patent/JP2014530861A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014537216A 2011-10-19 2012-10-18 Ｔｏｒキナーゼ阻害剤を用いたがんの処置 Pending JP2014530861A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161549034P 2011-10-19 2011-10-19
US61/549,034 2011-10-19
US201261591401P 2012-01-27 2012-01-27
US61/591,401 2012-01-27
US201261647233P 2012-05-15 2012-05-15
US61/647,233 2012-05-15
US201261653436P 2012-05-31 2012-05-31
US61/653,436 2012-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016234951A Division JP6360136B2 (ja) 2011-10-19 2016-12-02 Ｔｏｒキナーゼ阻害剤を用いたがんの処置

Publications (2)

Publication Number Publication Date
JP2014530861A true JP2014530861A (ja) 2014-11-20
JP2014530861A5 JP2014530861A5 (cg-RX-API-DMAC7.html) 2015-11-12

Family

ID=47116477

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014537216A Pending JP2014530861A (ja) 2011-10-19 2012-10-18 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2016234951A Active JP6360136B2 (ja) 2011-10-19 2016-12-02 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2018117932A Pending JP2018162286A (ja) 2011-10-19 2018-06-21 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2020117028A Pending JP2020169203A (ja) 2011-10-19 2020-07-07 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2021078559A Pending JP2021107461A (ja) 2011-10-19 2021-05-06 Ｔｏｒキナーゼ阻害剤を用いたがんの処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016234951A Active JP6360136B2 (ja) 2011-10-19 2016-12-02 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2018117932A Pending JP2018162286A (ja) 2011-10-19 2018-06-21 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2020117028A Pending JP2020169203A (ja) 2011-10-19 2020-07-07 Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP2021078559A Pending JP2021107461A (ja) 2011-10-19 2021-05-06 Ｔｏｒキナーゼ阻害剤を用いたがんの処置

Country Status (19)

Country Link
US (4) US9493466B2 (cg-RX-API-DMAC7.html)
EP (3) EP3466423B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014530861A (cg-RX-API-DMAC7.html)
KR (1) KR101978537B1 (cg-RX-API-DMAC7.html)
CN (2) CN103998036B (cg-RX-API-DMAC7.html)
BR (1) BR112014009755B1 (cg-RX-API-DMAC7.html)
CA (1) CA2852921C (cg-RX-API-DMAC7.html)
EA (2) EA034512B1 (cg-RX-API-DMAC7.html)
ES (2) ES2894958T3 (cg-RX-API-DMAC7.html)
IL (3) IL232128B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02887A (cg-RX-API-DMAC7.html)
MX (4) MX373925B (cg-RX-API-DMAC7.html)
MY (1) MY183661A (cg-RX-API-DMAC7.html)
PH (1) PH12014500869A1 (cg-RX-API-DMAC7.html)
SG (3) SG10201912850WA (cg-RX-API-DMAC7.html)
TW (4) TWI758746B (cg-RX-API-DMAC7.html)
UA (1) UA115319C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013059396A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201402771B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
JP2021113224A (ja) * 2015-11-20 2021-08-05 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
JP2023504021A (ja) * 2019-11-25 2023-02-01 メッドシャイン ディスカバリー インコーポレイテッド Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
AU2014223501A1 (en) * 2013-02-28 2015-09-17 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
KR20160002792A (ko) * 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
WO2014172425A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105358177B (zh) * 2013-04-17 2018-11-23 西格诺药品有限公司 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CN105792816A (zh) * 2013-10-04 2016-07-20 西格诺药品有限公司 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
WO2017136689A1 (en) * 2016-02-05 2017-08-10 Academia Sinica Purine compounds possessing anticancer activity
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
US20210254000A1 (en) * 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
HRP20250517T1 (hr) 2018-03-09 2025-06-20 Recurium Ip Holdings, Llc Supstituirani 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-oni
CN110526907B (zh) * 2018-05-23 2021-04-23 四川大学 苯并噁嗪酮类衍生物及其应用
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN119431323A (zh) 2019-07-31 2025-02-14 贝林格尔·英格海姆国际有限公司 作为cd38抑制剂的杂双环酰胺
TWI768550B (zh) * 2019-11-22 2022-06-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類螺環化合物及其衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506934A (ja) * 2006-10-19 2010-03-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
WO2011097333A1 (en) * 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE262026C (cg-RX-API-DMAC7.html)
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (cg-RX-API-DMAC7.html) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
CN1167420C (zh) 1997-09-26 2004-09-22 赞塔里斯有限公司 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
US20050033048A1 (en) 2000-12-12 2005-02-10 Rajagopal Bakthavatchalam Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
MXPA04002067A (es) 2001-09-04 2004-06-07 Boehringer Ingelheim Pharma Nuevas dihidropteridinonas, procedimientos para su preparacion y su uso como medicamento.
CA2462441A1 (en) 2001-10-18 2003-04-24 Pier F. Cirillo 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
JP2005530759A (ja) 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
WO2004042002A2 (en) 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
DK1599478T3 (da) 2003-02-26 2007-09-17 Boehringer Ingelheim Pharma Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004093918A2 (en) 2003-04-23 2004-11-04 Wyeth Holdings Corporation Peg-wortmannin conjugates
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
EP1641423B1 (en) 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepine cgrp receptor antagonists
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008514628A (ja) 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 蛋白質キナーゼ類のイミダゾ｛４，５−ｂ｝ピラジノン阻害剤
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
CA2604161A1 (en) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
CA2629245C (en) 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
DK2069352T5 (en) * 2006-08-02 2017-04-03 Cytokinetics Inc SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5590040B2 (ja) * 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
AU2009324894B2 (en) * 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
KR20120091240A (ko) * 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
SG11201402766UA (en) 2011-12-02 2014-06-27 Signal Pharm Llc PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-<i>B</i>]PYRAZIN-2(1<i>H</i>)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010506934A (ja) * 2006-10-19 2010-03-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
WO2011097333A1 (en) * 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
JP2021113224A (ja) * 2015-11-20 2021-08-05 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
JP7273886B2 (ja) 2015-11-20 2023-05-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
US12043623B2 (en) 2015-11-20 2024-07-23 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP2023504021A (ja) * 2019-11-25 2023-02-01 メッドシャイン ディスカバリー インコーポレイテッド Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
JP7383818B2 (ja) 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物

Also Published As

Publication number Publication date
US20170027932A1 (en) 2017-02-02
ZA201402771B (en) 2015-11-25
SG10201505102WA (en) 2015-07-30
TWI629983B (zh) 2018-07-21
US9937170B2 (en) 2018-04-10
US20180235960A1 (en) 2018-08-23
NZ710245A (en) 2016-11-25
CN107157990B (zh) 2020-01-07
IL281180A (en) 2021-04-29
TW201733585A (zh) 2017-10-01
NZ623759A (en) 2016-05-27
CN107157990A (zh) 2017-09-15
MX2020004689A (es) 2021-07-09
KR20140092336A (ko) 2014-07-23
IN2014CN02887A (cg-RX-API-DMAC7.html) 2015-07-03
CA2852921C (en) 2023-10-10
MX357833B (es) 2018-07-26
IL281180B (en) 2022-10-01
BR112014009755A2 (pt) 2017-04-25
CA2852921A1 (en) 2013-04-25
WO2013059396A3 (en) 2013-08-22
CN103998036A (zh) 2014-08-20
TW201733584A (zh) 2017-10-01
EP3466423B1 (en) 2021-07-28
SG10201912850WA (en) 2020-02-27
PH12014500869A1 (en) 2014-06-30
EA201490814A1 (ru) 2014-09-30
MX373925B (es) 2020-07-10
WO2013059396A2 (en) 2013-04-25
ES2751921T3 (es) 2020-04-02
ZA201407793B (en) 2016-08-31
ES2894958T3 (es) 2022-02-16
TW202034922A (zh) 2020-10-01
HK1243919A1 (zh) 2018-07-27
BR112014009755B1 (pt) 2022-09-13
IL256828B (en) 2021-04-29
JP2017039780A (ja) 2017-02-23
SG11201401630SA (en) 2014-05-29
IL232128A0 (en) 2014-05-28
JP6360136B2 (ja) 2018-07-18
TWI708605B (zh) 2020-11-01
EP2768500B1 (en) 2019-08-21
EA201890768A2 (ru) 2018-08-31
TWI713752B (zh) 2020-12-21
KR101978537B1 (ko) 2019-05-14
US9493466B2 (en) 2016-11-15
IL281180B2 (en) 2023-02-01
IL256828A (en) 2018-03-29
US20220273650A1 (en) 2022-09-01
MX384385B (es) 2025-03-14
JP2021107461A (ja) 2021-07-29
US20130102613A1 (en) 2013-04-25
EP2768500A2 (en) 2014-08-27
EP3466423A2 (en) 2019-04-10
EP3659599A1 (en) 2020-06-03
EP3466423A3 (en) 2019-07-03
JP2020169203A (ja) 2020-10-15
UA115319C2 (uk) 2017-10-25
US11166950B2 (en) 2021-11-09
TWI758746B (zh) 2022-03-21
CN103998036B (zh) 2017-05-31
EA030664B1 (ru) 2018-09-28
IL232128B (en) 2018-01-31
EP3659599B1 (en) 2022-12-21
MX2014004775A (es) 2015-01-16
EA034512B1 (ru) 2020-02-14
EA201890768A3 (ru) 2018-12-28
MX348566B (es) 2017-06-20
TW201318626A (zh) 2013-05-16
MY183661A (en) 2021-03-05
JP2018162286A (ja) 2018-10-18

Similar Documents

Publication Publication Date Title
JP6360136B2 (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの処置
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2018052963A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2015510891A (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
AU2015200318B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2012318272B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40006113B (en) Treatment of cancer with tor kinase inhibitors
HK40006113A (en) Treatment of cancer with tor kinase inhibitors
HK1243919B (zh) 利用tor激酶抑制剂治疗癌症
HK1195511A (en) Treatment of cancer with tor kinase inhibitors
HK1195511B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161004